POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.

根据FDA的要求，承包商将根据FDA的要求，开发一种生物剂量测量设备，以应对RAD-NUC事件。急救者社区最迫切的需要之一是对受影响人口进行快速分类，以便将受害者与可用于抗逆转录病毒治疗的适当和有限的护理相匹配。为了应对这一对我国国家安全的紧迫威胁，承包商提议开发一种基于miRNA的循环组织特定辐射生物剂量计(MiDOS)。

The contractor, in pursuit of licensure and in accordance with the FDA, will develop a biodosimetry device in response to a RAD-NUC incident. One of the most urgent needs of the first responder community is to perform rapid triage of the affected population in order to match victims with appropriate and limited care available to manage for ARS.2. In response to this urgent risk to our national security, the contractor proposes to develop a circulating miRNA based tissue specific radiation biodosimeter (miDOS).